These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 25971275)
1. [Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation]. Hatsuse M; Taniguchi-Yoshihara K; Yagyu S; Fuchida S; Okano A; Murakami S; Shimazaki C Rinsho Ketsueki; 2015 Apr; 56(4):428-31. PubMed ID: 25971275 [TBL] [Abstract][Full Text] [Related]
2. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521 [TBL] [Abstract][Full Text] [Related]
3. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D; Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400 [TBL] [Abstract][Full Text] [Related]
4. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]. Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701 [TBL] [Abstract][Full Text] [Related]
5. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737 [TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
10. Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Singhal S; Safdar A; Chiang KY; Godder K; van Rhee F; Garner F; Foster B; Dubovsky D; Henslee-Downey PJ; Mehta J Bone Marrow Transplant; 2000 Dec; 26(11):1231-3. PubMed ID: 11149738 [TBL] [Abstract][Full Text] [Related]
11. Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma. Tapprich C; Fenk R; Schneider P; Bernhardt A; Haas R; Kobbe G Bone Marrow Transplant; 2003 Sep; 32(6):629-31. PubMed ID: 12953137 [TBL] [Abstract][Full Text] [Related]
12. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436 [TBL] [Abstract][Full Text] [Related]
13. Outcome of unrelated transplants in patients with multiple myeloma. Ballen KK; King R; Carston M; Kollman C; Nelson G; Lim S; Reece D; Giralt S; Vesole DH Bone Marrow Transplant; 2005 Apr; 35(7):675-81. PubMed ID: 15723085 [TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation]. Fuchida SI; Shimura K; Taminishi-Katsuragawa Y; Matsui-Maegawa S; Okano A; Hatsuse M; Murakami S; Shimazaki C Rinsho Ketsueki; 2019; 60(10):1468-1470. PubMed ID: 31695009 [TBL] [Abstract][Full Text] [Related]
15. Autologous red cell recovery and relapse of multiple myeloma after bone marrow transplantation: is this a graft-versus-myeloma effect? Forsyth C; Nelson M; Popp H; Snowdon L; Gibson J; Joshua D Bone Marrow Transplant; 1996 Mar; 17(3):457-9. PubMed ID: 8704707 [TBL] [Abstract][Full Text] [Related]
16. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ; Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917 [TBL] [Abstract][Full Text] [Related]
17. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Gahrton G; Svensson H; Björkstrand B; Apperley J; Carlson K; Cavo M; Ferrant A; Fouillard L; Gratecos N; Gratwohl A; Guilhot F; Lambertenghi Deliliers G; Ljungman P; Masszi T; Milligan DW; Powles RL; Reiffers J; Samson JD; Stoppa AM; Vernant JP; Volin L; Wallvik J Bone Marrow Transplant; 1999 Oct; 24(7):741-5. PubMed ID: 10516677 [TBL] [Abstract][Full Text] [Related]
18. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279 [TBL] [Abstract][Full Text] [Related]